Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Clinical trial NCT02953457 · COMPLETED

Trial details

NCT number: NCT02953457
Sponsor: Roswell Park Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

BRCA1 Gene Mutation BRCA2 Gene Mutation Ovarian Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma

Start date: 2017-06-29
Primary completion: 2021-09-15
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.